{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:00:30Z","timestamp":1791547230478,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Castrate resistant prostate cancer (CRPC) is often driven by constitutively active androgen receptor and AR splicing variants that become resistant to established hormonal therapy strategies such as enzalutamide. Deubiquitinating enzymes (DUBs) play crucial roles in cancer development, progression, and metastasis by epigenetic modification. Hence, targeting DUBs might prove to be a valid strategy for developing novel anti-cancer therapeutics. Here, we reveal that the deubiquitinating enzyme USP13 is up-regulated in PCa tissues and correlates with prostate cancer progression. USP13 silencing inhibits prostate cancer cell growth in vitro and in vivo. Mechanically, USP13 directly interacts with PCMT1 and removes polyubiquitination of PCMT1 to maintain its stability, which promotes PCa cell proliferation and enzalutamide resistance. Depletion of USP13 promoted PCa cells sensitive to enzalutamide. Clinically, USP13 was significantly up-regulated in prostate cancer tissues and positively associated with PCMT1 expression. Notably, inhibition of USP13 significantly decreases prostate tumor growth and improves enzalutamide treatments through PCMT1 suppression. Our studies demonstrate that inhibition of USP13 can offer a viable therapeutic option to overcome enzalutamide resistance in prostate cancer patients with USP13\/PCMT1-overexpression.<\/jats:p>","DOI":"10.1038\/s41419-026-08824-9","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:16:07Z","timestamp":1777515367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["USP13 promotes enzalutamide resistance by catalyzing depolyubiquitination of PCMT1 in prostate cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Zhipeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruize","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuchun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Situ","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6686-7561","authenticated-orcid":false,"given":"Bin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0269-9129","authenticated-orcid":false,"given":"Songhui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"8824_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bph.15300","volume":"178","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, et al. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021;178:239\u201361.","journal-title":"Br J Pharmacol"},{"key":"8824_CR2","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.chembiol.2021.04.021","volume":"28","author":"RS Magin","year":"2021","unstructured":"Magin RS, Liu X, Felix A, Bratt AS, Chan WC, Buhrlage SJ. Small molecules as tools for functional assessment of deubiquitinating enzyme function. Cell Chem Biol. 2021;28:1090\u2013100.","journal-title":"Cell Chem Biol"},{"key":"8824_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1146\/annurev-biochem-061516-044916","volume":"86","author":"TET Mevissen","year":"2017","unstructured":"Mevissen TET, Komander D. Mechanisms of deubiquitinase specificity and regulation. Annu Rev Biochem. 2017;86:159\u201392.","journal-title":"Annu Rev Biochem"},{"key":"8824_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00018-024-05187-2","volume":"81","author":"JK Karapurkar","year":"2024","unstructured":"Karapurkar JK, Colaco JC, Suresh B, Tyagi A, Woo SH, Jo WJ, et al. USP28 promotes tumorigenesis and cisplatin resistance by deubiquitinating MAST1 protein in cancer cells. Cell Mol Life Sci. 2024;81:145.","journal-title":"Cell Mol Life Sci"},{"key":"8824_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113511","volume":"42","author":"Y Guo","year":"2023","unstructured":"Guo Y, Tian J, Guo Y, Wang C, Chen C, Cai S, et al. Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating beta-catenin. Cell Rep. 2023;42:113511.","journal-title":"Cell Rep"},{"key":"8824_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.899987","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Lin W, Li R, Cheng H, Sun S, Shao F, et al. The deubiquitinase USP13 maintains cancer cell stemness by promoting FASN stability in small cell lung cancer. Front Oncol. 2022;12:899987.","journal-title":"Front Oncol"},{"key":"8824_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15752","volume":"8","author":"Y Li","year":"2017","unstructured":"Li Y, Luo K, Yin Y, Wu C, Deng M, Li L, et al. USP13 regulates the RAP80-BRCA1 complex dependent DNA damage response. Nat Commun. 2017;8:15752.","journal-title":"Nat Commun"},{"key":"8824_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167599","volume":"1871","author":"Q Wang","year":"2025","unstructured":"Wang Q, Cao S, Sun Z, Zhu W, Sun L, Li Y, et al. USP13 inhibition exacerbates mitochondrial dysfunction and acute kidney injury by acting on MCL-1. Biochim Biophys Acta Mol Basis Dis. 2025;1871:167599.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"8824_CR9","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/j.celrep.2020.01.088","volume":"30","author":"W Xie","year":"2020","unstructured":"Xie W, Jin S, Wu Y, Xian H, Tian S, Liu DA, et al. Auto-ubiquitination of NEDD4-1 recruits USP13 to facilitate autophagy through deubiquitinating VPS34. Cell Rep. 2020;30:2807\u201319.e2804.","journal-title":"Cell Rep"},{"key":"8824_CR10","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.1038\/s41388-020-01396-8","volume":"39","author":"M Esposito","year":"2020","unstructured":"Esposito M, Akman HB, Giron P, Ceregido MA, Schepers R, Ramos Paez LC, et al. USP13 controls the stability of Aurora B impacting progression through the cell cycle. Oncogene. 2020;39:6009\u201323.","journal-title":"Oncogene"},{"key":"8824_CR11","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/s41388-021-01679-8","volume":"40","author":"EL Morgan","year":"2021","unstructured":"Morgan EL, Patterson MR, Barba-Moreno D, Scarth JA, Wilson A, Macdonald A. The deubiquitinase (DUB) USP13 promotes Mcl-1 stabilisation in cervical cancer. Oncogene. 2021;40:2112\u201329.","journal-title":"Oncogene"},{"key":"8824_CR12","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/ncb2874","volume":"15","author":"J Zhang","year":"2013","unstructured":"Zhang J, Zhang P, Wei Y, Piao HL, Wang W, Maddika S, et al. Deubiquitylation and stabilization of PTEN by USP13. Nat cell Biol. 2013;15:1486\u201394.","journal-title":"Nat cell Biol"},{"key":"8824_CR13","doi-asserted-by":"publisher","first-page":"9119","DOI":"10.1073\/pnas.1100028108","volume":"108","author":"M Chen","year":"2011","unstructured":"Chen M, Gutierrez GJ, Ronai ZA. Ubiquitin-recognition protein Ufd1 couples the endoplasmic reticulum (ER) stress response to cell cycle control. Proc Natl Acad Sci USA. 2011;108:9119\u201324.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8824_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1421","volume":"2","author":"X Zhao","year":"2011","unstructured":"Zhao X, Fiske B, Kawakami A, Li J, Fisher DE. Regulation of MITF stability by the USP13 deubiquitinase. Nat Commun. 2011;2:414.","journal-title":"Nat Commun"},{"key":"8824_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1084\/jem.20151673","volume":"214","author":"X Fang","year":"2017","unstructured":"Fang X, Zhou W, Wu Q, Huang Z, Shi Y, Yang K, et al. Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination. J Exp Med. 2017;214:245\u201367.","journal-title":"J Exp Med"},{"key":"8824_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2021.103063","volume":"100","author":"W Kim","year":"2021","unstructured":"Kim W, Zhao F, Gao H, Qin S, Hou J, Deng M, et al. USP13 regulates the replication stress response by deubiquitinating TopBP1. DNA repair. 2021;100:103063.","journal-title":"DNA repair"},{"key":"8824_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13046-019-1262-4","volume":"38","author":"X Man","year":"2019","unstructured":"Man X, Piao C, Lin X, Kong C, Cui X, Jiang Y. USP13 functions as a tumor suppressor by blocking the NF-kB-mediated PTEN downregulation in human bladder cancer. J Exp Clin Cancer Res. 2019;38:259.","journal-title":"J Exp Clin Cancer Res"},{"key":"8824_CR18","doi-asserted-by":"publisher","first-page":"9175","DOI":"10.2147\/CMAR.S186829","volume":"11","author":"Z Qu","year":"2019","unstructured":"Qu Z, Zhang R, Su M, Liu W. USP13 serves as a tumor suppressor via the PTEN\/AKT pathway in oral squamous cell carcinoma. Cancer Manag Res. 2019;11:9175\u201383.","journal-title":"Cancer Manag Res"},{"key":"8824_CR19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2119854119","volume":"119","author":"H Xie","year":"2022","unstructured":"Xie H, Zhou J, Liu X, Xu Y, Hepperla AJ, Simon JM, et al. USP13 promotes deubiquitination of ZHX2 and tumorigenesis in kidney cancer. Proc Natl Acad Sci USA. 2022;119:e2119854119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8824_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02693-9","volume":"9","author":"S Zhang","year":"2018","unstructured":"Zhang S, Zhang M, Jing Y, Yin X, Ma P, Zhang Z, et al. Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors. Nat Commun. 2018;9:215.","journal-title":"Nat Commun"},{"key":"8824_CR21","doi-asserted-by":"crossref","first-page":"11654","DOI":"10.18632\/aging.205104","volume":"15","author":"J Zhong","year":"2023","unstructured":"Zhong J, Yuan C, Liu L, Du Y, Hui Y, Chen Z, et al. PCMT1 regulates the migration, invasion, and apoptosis of prostate cancer through modulating the PI3K\/AKT\/GSK-3beta pathway. Aging. 2023;15:11654\u201371.","journal-title":"Aging"},{"key":"8824_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.650999","volume":"9","author":"LM Dong","year":"2021","unstructured":"Dong LM, Zhang XL, Mao MH, Li YP, Zhang XY, Xue DW, et al. LINC00511\/miRNA-143-3p modulates apoptosis and malignant phenotype of bladder carcinoma cells via PCMT1. Front Cell Dev Biol. 2021;9:650999.","journal-title":"Front Cell Dev Biol"},{"key":"8824_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/iub.1717","volume":"70","author":"L Dong","year":"2018","unstructured":"Dong L, Li Y, Xue D, Liu Y. PCMT1 is an unfavorable predictor and functions as an oncogene in bladder cancer. IUBMB Life. 2018;70:291\u20139.","journal-title":"IUBMB Life"},{"key":"8824_CR24","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1038\/s41388-023-02739-x","volume":"42","author":"C Ma","year":"2023","unstructured":"Ma C, Wang D, Tian Z, Gao W, Zang Y, Qian L, et al. USP13 deubiquitinates and stabilizes cyclin D1 to promote gastric cancer cell cycle progression and cell proliferation. Oncogene. 2023;42:2249\u201362.","journal-title":"Oncogene"},{"key":"8824_CR25","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41418-022-01107-8","volume":"30","author":"Z Gao","year":"2023","unstructured":"Gao Z, Li C, Sun H, Bian Y, Cui Z, Wang N, et al. N(6)-methyladenosine-modified USP13 induces pro-survival autophagy and imatinib resistance via regulating the stabilization of autophagy-related protein 5 in gastrointestinal stromal tumors. Cell Death Differ. 2023;30:544\u201359.","journal-title":"Cell Death Differ"},{"key":"8824_CR26","doi-asserted-by":"publisher","first-page":"59781","DOI":"10.18632\/oncotarget.10926","volume":"7","author":"J Hoefer","year":"2016","unstructured":"Hoefer J, Akbor M, Handle F, Ofer P, Puhr M, Parson W, et al. Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide. Oncotarget. 2016;7:59781\u201394.","journal-title":"Oncotarget"},{"key":"8824_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07178-x","volume":"9","author":"C Liu","year":"2018","unstructured":"Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP, et al. Proteostasis by STUB1\/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. Nat Commun. 2018;9:4700.","journal-title":"Nat Commun"},{"key":"8824_CR28","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1158\/0008-5472.CAN-14-3080","volume":"75","author":"C Liu","year":"2015","unstructured":"Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, et al. Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer. Cancer Res. 2015;75:1413\u201322.","journal-title":"Cancer Res"},{"key":"8824_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/path.5495","volume":"252","author":"DE Tang","year":"2020","unstructured":"Tang DE, Dai Y, He JX, Lin LW, Leng QX, Geng XY, et al. Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer. J Pathol. 2020;252:101\u201313.","journal-title":"J Pathol"},{"key":"8824_CR30","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.7150\/ijbs.82081","volume":"19","author":"C Wang","year":"2023","unstructured":"Wang C, Meng Y, Zhao J, Ma J, Zhao Y, Gao R, et al. Deubiquitinase USP13 regulates glycolytic reprogramming and progression in osteosarcoma by stabilizing METTL3\/m(6)A\/ATG5 axis. Int J Biol Sci. 2023;19:2289\u2013303.","journal-title":"Int J Biol Sci"},{"key":"8824_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167291","volume":"1870","author":"SV Kona","year":"2024","unstructured":"Kona SV, Kalivendi SV. The USP10\/13 inhibitor, spautin-1, attenuates the progression of glioblastoma by independently regulating RAF-ERK mediated glycolysis and SKP2. Biochim Biophys Acta Mol Basis Dis. 2024;1870:167291.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"8824_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cell.2011.08.037","volume":"147","author":"J Liu","year":"2011","unstructured":"Liu J, Xia H, Kim M, Xu L, Li Y, Zhang L, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell. 2011;147:223\u201334.","journal-title":"Cell"},{"key":"8824_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02869-z","volume":"12","author":"K Hu","year":"2025","unstructured":"Hu K, Li J, Chen K, Mi X, Pan Y, Tang J, et al. Hypoxia-induced USP13 expression drives ferroptosis resistance and tumor immune evasion in hepatocellular carcinoma through the stabilization of ACLY. Cell Death Discov. 2025;12:28.","journal-title":"Cell Death Discov"},{"key":"8824_CR34","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1016\/j.apsb.2025.03.051","volume":"15","author":"L Lin","year":"2025","unstructured":"Lin L, Han J, Xu D, Fang Z, Ye B, Qian J, et al. Deubiquitinase USP13 alleviates doxorubicin-induced cardiotoxicity through promoting the autophagy-mediated degradation of STING. Acta Pharm Sin B. 2025;15:2545\u201358.","journal-title":"Acta Pharm Sin B"},{"key":"8824_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15534","volume":"8","author":"H Sun","year":"2017","unstructured":"Sun H, Zhang Q, Jing YY, Zhang M, Wang HY, Cai Z, et al. USP13 negatively regulates antiviral responses by deubiquitinating STING. Nat Commun. 2017;8:15534.","journal-title":"Nat Commun"},{"key":"8824_CR36","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1016\/j.drudis.2022.06.009","volume":"27","author":"F Ge","year":"2022","unstructured":"Ge F, Li Y, Yuan T, Wu Y, He Q, Yang B, et al. Deubiquitinating enzymes: promising targets for drug resistance. Drug Discov today. 2022;27:2603\u201313.","journal-title":"Drug Discov today"},{"key":"8824_CR37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.molcel.2016.05.009","volume":"63","author":"SA Abdul Rehman","year":"2016","unstructured":"Abdul Rehman SA, Kristariyanto YA, Choi SY, Nkosi PJ, Weidlich S, Labib K, et al. MINDY-1 is a member of an evolutionarily conserved and structurally distinct new family of deubiquitinating enzymes. Mol cell. 2016;63:146\u201355.","journal-title":"Mol cell"},{"key":"8824_CR38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S1568-1637(03)00011-4","volume":"2","author":"S Clarke","year":"2003","unstructured":"Clarke S. Aging as war between chemical and biochemical processes: protein methylation and the recognition of age-damaged proteins for repair. Ageing Res Rev. 2003;2:263\u201385.","journal-title":"Ageing Res Rev"},{"key":"8824_CR39","doi-asserted-by":"publisher","first-page":"10380","DOI":"10.1073\/pnas.181347498","volume":"98","author":"Y Zhu","year":"2001","unstructured":"Zhu Y, Qi C, Cao WQ, Yeldandi AV, Rao MS, Reddy JK. Cloning and characterization of PIMT, a protein with a methyltransferase domain, which interacts with and enhances nuclear receptor coactivator PRIP function. Proc Natl Acad Sci USA. 2001;98:10380\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8824_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.612343","volume":"11","author":"R Soliman","year":"2020","unstructured":"Soliman R, Cordero-Maldonado ML, Martins TG, Moein M, Conrotte JF, Warmack RA, et al. l-Isoaspartyl methyltransferase deficiency in zebrafish leads to impaired calcium signaling in the brain. Front Genet. 2020;11:612343.","journal-title":"Front Genet"},{"key":"8824_CR41","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s40265-018-1029-9","volume":"78","author":"LJ Scott","year":"2018","unstructured":"Scott LJ. Enzalutamide: a review in castration-resistant prostate cancer. Drugs. 2018;78:1913\u201324.","journal-title":"Drugs"},{"key":"8824_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104500","volume":"90","author":"CL Hung","year":"2023","unstructured":"Hung CL, Liu HH, Fu CW, Yeh HH, Hu TL, Kuo ZK, et al. Targeting androgen receptor and the variants by an orally bioavailable proteolysis targeting chimeras compound in castration resistant prostate cancer. EBioMedicine. 2023;90:104500.","journal-title":"EBioMedicine"},{"key":"8824_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccell.2019.01.008","volume":"35","author":"L Cato","year":"2019","unstructured":"Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, et al. ARv7 represses tumor-suppressor genes in castration-resistant prostate cancer. Cancer cell. 2019;35:401\u201313.e406.","journal-title":"Cancer cell"},{"key":"8824_CR44","first-page":"365","volume":"4","author":"T Chandrasekar","year":"2015","unstructured":"Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4:365\u201380.","journal-title":"Transl Androl Urol"},{"key":"8824_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10424-7","volume":"22","author":"X Cui","year":"2022","unstructured":"Cui X, Yu H, Yao J, Li J, Li Z, Jiang Z. ncRNA-mediated overexpression of ubiquitin-specific proteinase 13 contributes to the progression of prostate cancer via modulating AR signaling, DNA damage repair and immune infiltration. BMC Cancer. 2022;22:1350.","journal-title":"BMC Cancer"},{"key":"8824_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117251","volume":"242","author":"X Chen","year":"2025","unstructured":"Chen X, Ma Y, Liu H, Wang Y. Multifunctional regulation and treatment of ubiquitin specific protease 10. Biochem Pharmacol. 2025;242:117251.","journal-title":"Biochem Pharmacol"},{"key":"8824_CR47","doi-asserted-by":"crossref","unstructured":"Liu X, Balaraman K, Lynch CC, Hebron M, Wolf C, Moussa C. Novel ubiquitin specific protease-13 inhibitors alleviate neurodegenerative pathology. Metabolites 2021;11:622.","DOI":"10.3390\/metabo11090622"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08824-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08824-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08824-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:02:07Z","timestamp":1781658127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08824-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8824"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08824-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The animal experiments performed here have been approved by the Animal Protection and Use Committee of The First Affiliated Hospital of Nanchang University (approval number: CDYFY-IACUC-202407QR186). Clinic tissue sample collection was approved by the Internal Review and Ethics Boards of the First Affiliated Hospital of Nanchang University (Registration number: (2024) CDYFYYLK(10-026)). Informed consent was obtained from all participants, and all methods were performed in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"576"}}